Developer docs
API playgroundTry for free, no card

Search company profiles

3D BioFibR

Full company profile

uuid0000xkb

Namestring
3D BioFibR
Legal namestring
3DBioFibR Inc.
Websiteurl
3dbiofibr.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

3D BioFibR is a Halifax, Nova Scotia-based biotechnology and advanced materials company founded in 2020 that commercializes a patented automated dry-spinning platform for producing biomimetic protein fibers at commercial scale. The company's flagship CollaFibR® product line consists of collagen fibers that closely replicate the structure, biomechanics, and biochemistry of natural collagen, with the company claiming over 1000x the throughput of competing technologies and first-mover status in commercial-scale collagen fiber spinning. The same platform has been used to produce recombinant spider silk (SpidrFibR™ — claimed to be five times stronger than steel), fibrin, and chitosan, indicating applicability across multiple network-forming biopolymers. The company is led by CEO Kevin Sullivan (23+ years of biotech leadership and a prior TSX IPO) and CSO Dr. John Frampton (Tier II Canada Research Chair at Dalhousie University, 40+ publications, 2 patents).

3D BioFibR generates revenue through three channels: direct e-commerce sales of two catalog SKUs (μCollaFibR™ Additive for Bioinks and Hydrogels, and CollaFibR® 3D Scaffold for Cell Culture) via its own online storefront; regional distribution through five specialty life-science distributors (AMSBIO in the Americas/Europe, AMS Biotechnology in Europe, Cell & Gene BioSolutions in India, Sciencewerke in Singapore/Malaysia, and Filgen in Japan); and project-based custom non-woven collagen scaffold manufacturing for enterprise tissue-engineering customers. Bespoke co-development engagements include a 'bionic' nerve project with ReNerve and a plant-based recombinant human collagen program with PlantForm Corporation (supported by $1.3M from NGen). Customers are primarily academic and commercial tissue-engineering, 3D bioprinting, and regenerative medicine researchers, with secondary exploration of advanced-materials verticals such as green textiles, aerospace, and defense.

The company is privately held and venture-backed, having raised approximately CAD $8.07M in equity across four rounds (October 2020, September 2021, July 2023, and June 2025) plus CAD $1.5M in non-dilutive grants from ACOA and NGen. Current capital priorities are manufacturing capacity expansion and the construction of a new clean room in Halifax for medical-grade materials production. The 11–50-person organization was recognized as Most Innovative Company at the 2024 Discovery Awards and is positioning for regulated tissue-engineering and regenerative-medicine supply as its manufacturing footprint scales.

Short descriptiontext

3D BioFibR is a Halifax-based biotech company that uses patented automated dry-spinning technology to manufacture commercial-scale collagen and other biopolymer fibers for tissue engineering, 3D bioprinting, and regenerative medicine researchers worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHalifax, Canada
HQ citystring
Halifax
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopolymer fiber manufacturing, collagen fiber products, tissue engineering materials, dry-spinning technology, 3D bioprinting materials
Industry2 codes
PRIMARYIMANAAAG
Bio-based & Biodegradable Polymer Resin Manufacturing (PLA, PHA, PBS, starch blends)
SECONDARYIMAAADAA
Polymer 3D Printing Service Bureaus (FDM/FFF, SLA/DLP, SLS/MJF)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Services (On-Demand Manufacturing & Service Bureaus)
NAICS code2 codes
  • Plastics Material and Resin Manufacturing325211
  • Resin and Synthetic Rubber Manufacturing32521
SIC code2 codes
  • Plastic Materials, Synth Resins & Nonvulcan Elastomers2821
  • Plastic Material, Synth Resin/Rubber, Cellulos (No Glass)2820
Product category
Biopolymer Fiber Materials
Social media profiles1 record
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model4 records
1Direct product sales via e-commerce storefront
TypeHardware Sales
Description

Online storefront at shop.3dbiofibr.com sells CollaFibR tissue engineering products directly to end users, including μCollaFibR™ additive for bioinks and hydrogels and CollaFibR® 3D Scaffold for Cell Culture. Transactional, unit-priced purchases.

3dbiofibr.com
2Distributor-led sales in regional markets
TypeTransaction Fee
Description

Revenue generated through regional distribution partners (AMSBIO in Americas/Europe, Cell & Gene BioSolutions in India, Sciencewerke in Singapore & Malaysia, Filgen in Japan) reselling CollaFibR products to local research customers.

3dbiofibr.com
3Custom scaffold manufacturing services
TypeProfessional Services
Description

Project-based custom non-woven collagen scaffold manufacturing for tissue engineering customers with bespoke specifications, sold directly via the company.

3dbiofibr.com
4Non-dilutive co-development and grant funding
TypeLicensing Royalties
Description

Funding from Next Generation Manufacturing Canada ($1.3M) and ACOA ($200,000) supporting R&D and automation projects. While not core revenue, supports scaling of commercial product offerings.

entrevestor.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels7 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1CollaFibR products sold via online storefront and regional distributors; specific prices not publicly listed
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Pricing is not publicly disclosed. Customers can purchase μCollaFibR™ Additive for Bioinks and Hydrogels and CollaFibR® 3D Scaffold for Cell Culture (12-well plate inserts) directly or via regional distributors.

3dbiofibr.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1CollaFibR
Description

Patented collagen fiber product line produced using 3DBioFibR's dry-spinning technology, including the μCollaFibR additive for bioinks and hydrogels and the CollaFibR 3D Scaffold for cell culture. Used for 3D bioprinting, hydrogels, and tissue engineering applications.

3dbiofibr.com
+2 more records
Core offering1 text field

3D BioFibR manufactures biomimetic collagen fibers and other biopolymer fibers using its patented, fully automated dry-spinning technology, delivering over 1000X the throughput of competing approaches. The company sells its CollaFibR® product family (μCollaFibR™ Additive for Bioinks and Hydrogels and CollaFibR® 3D Scaffold for Cell Culture) directly and via a global distributor network for tissue engineering, 3D bioprinting, and cell culture applications, and offers bespoke Custom Scaffolds and the SpidrFibR™ spider silk prototype.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 1000X the throughput of competing dry-spinning/collagen technologies
+3 more records
Product overview1 text field

3D BioFibR is a biotech company built around a single patented, fully automated dry-spinning platform that produces biopolymer fibers at commercial scale (over 1000× the throughput of competing technologies). The platform's flagship output is the CollaFibR® family of collagen fibers, which replicate the structure, biomechanics, and biochemical properties of natural collagen. CollaFibR® is commercialized as two catalog SKUs — μCollaFibR™ Additive for Bioinks and Hydrogels and CollaFibR® 3D Scaffold for Cell Culture — sold directly and through a global distributor network (AMSBIO in the Americas/Europe, Cell & Gene BioSolutions in India, Sciencewerke in Singapore/Malaysia, and Filgen in Japan). Beyond collagen, the same dry-spinning platform is used to spin other network-forming biopolymers, exemplified by the SpidrFibR™ recombinant spider silk prototype. Custom non-woven collagen scaffolds for tissue engineering are offered on a made-to-order basis through the Custom Scaffolds line, and the company is collaborating with PlantForm Corporation on plant-based recombinant human collagen fiber production and with ReNerve on a 'bionic' nerve project.

Product and service4 records
1μCollaFibR™ Additive for Bioinks and Hydrogels
CategoryBioprinting and hydrogel additive
Description

50 μm type I collagen fibers used as an additive for bioinks and hydrogels, universally compatible with bioprinting materials and modalities, chemically stable in solvents with pH >2, and acts as a physiologically relevant site for cell attachment while improving shape fidelity of bioprinted constructs. For tissue engineering and 3D bioprinting researchers.

2CollaFibR® 3D Scaffold for Cell Culture
Category3D cell culture scaffold
Description

100 μm porous collagen fiber scaffold resembling natural three-dimensional collagen structures, produced using automated robotics and GMP grade type I collagen (bovine) for high batch-to-batch consistency, provided in user-friendly 12-well plate inserts and compatible with brightfield, epifluorescence, confocal, and live cell microscopy. For tissue engineering researchers.

3SpidrFibR™ Recombinant Spider Silk
CategoryHigh-performance biopolymer fiber
Description

Recombinant spider silk prototype produced using 3D BioFibR's patented dry-spinning technology, described as five times stronger than steel and more extensible than rubber. Targeted at green textiles, aerospace engineering, and defense applications.

4Custom Scaffolds
CategoryCustom tissue engineering scaffolds
Description

Bespoke non-woven collagen scaffolds for tissue engineering produced via 3D BioFibR's patented dry-spinning technology, sold directly to clients with project-based specifications.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-18
Description

PlantForm Corporation is a co-development collaborator that received $1.3M from NGen jointly with 3D BioFibR. The project combines PlantForm's plant-based biologics platform with 3D BioFibR's fiber manufacturing technology to produce collagen fibers that mimic natural properties.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-28
Description

ReNerve and 3D BioFibR partnered for a 'bionic' nerve project to develop nerve repair solutions using CollaFibR collagen fiber technology.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

AMSBIO LLC. is 3D BioFibR's distributor for the Americas, based at 1035 Cambridge Street, Suite 11 B, Cambridge, MA 02141. They resell CollaFibR tissue engineering products via their website (amsbio.com).

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

AMS Biotechnology (Europe) Ltd. is 3D BioFibR's European distributor, based at 184 Park Drive, Milton Park, Abingdon OX14 4SE, U.K. They resell CollaFibR products to research customers across Europe.

Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Cell & Gene BioSolutions is 3D BioFibR's distributor in India, based at 418-B Rampriya Brundavan Gardenia, 4th Main, 4th Cross, Hanumgiri, Arehalli, Bangalore-560061, Karnataka, India.

Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Sciencewerke Pte Ltd is 3D BioFibR's distributor for Singapore and Malaysia, based at 102E Pasir Panjang Rd #08-03 Citilink Warehouse Complex, Singapore 118529.

Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Filgen Inc. is 3D BioFibR's distributor in Japan, based at 02E Pasir Panjan 1-409, Jonoyama, Midori-ku, Nagoya, Aichi-pref. 459-8011, Japan.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Collagen Solutions (Rousselot)
TypeBroad incumbent
Description

Rousselot (which acquired Collagen Solutions) is a global leader in collagen-based solutions for biomedical, pharmaceutical, and food applications. Directly comparable to 3D BioFibR as a supplier of medical-grade collagen materials for tissue engineering and regenerative medicine, but at significantly larger scale with established GMP manufacturing.

2Advanced BioMatrix
TypeDirect peer
Description

Advanced BioMatrix is a U.S.-based supplier of collagen, hyaluronic acid, and other extracellular matrix products used in 3D bioprinting, tissue engineering, and cell culture. Directly comparable to 3D BioFibR as a catalog supplier of biomaterials to the same research-tool and tissue-engineering customer base, though without a dry-spinning fiber platform.

TypeDirect peer
Description

Jellagen manufactures marine (jellyfish) collagen-based biomaterials for medical devices, 3D cell culture, and tissue engineering. Directly comparable to 3D BioFibR as a specialist collagen supplier targeting the same research and regenerative-medicine segments, with a differentiated raw material source.

TypeBroad incumbent
Description

BICO/Cellink is a global bioconvergence company providing bioprinters, bioinks, and biomaterials for 3D cell culture and tissue engineering. Comparable to 3D BioFibR as a supplier into the bioprinting workflow, but at much broader portfolio scale and with bioprinter hardware alongside bioinks.

TypeDirect peer
Description

Matricel is a German manufacturer of collagen-based scaffolds and medical devices for tissue engineering and regenerative medicine. Directly comparable to 3D BioFibR as a specialist collagen scaffold producer, though focused on processed collagen matrices rather than spun collagen fibers.

TypeBroad incumbent
Description

Collagen Matrix is a U.S. manufacturer of collagen and other natural polymer-based medical devices for tissue repair and regeneration. Comparable to 3D BioFibR as a medical-grade collagen products supplier, but operating at larger scale with established FDA-cleared products.

TypeBroad incumbent
Description

DSM Biomedical (part of dsm-firmenich) is a global supplier of biomaterials including collagen, hyaluronic acid, and resorbable polymers for medical devices and tissue engineering. Comparable to 3D BioFibR as a regulated medical-grade biomaterials supplier, but at vastly larger scale and broader portfolio scope.

TypeBroad incumbent
Description

Corbion is a Dutch biobased ingredients company with biomedical-grade biopolymers used in medical devices and regenerative medicine. Comparable to 3D BioFibR as a biomaterials supplier targeting medical and life-science customers, but at much broader scope and corporate scale.

TypeDirect peer
Description

Spiber is a Japanese biotechnology company producing Brewed Protein (recombinant spider silk) materials for textiles, automotive, and other applications. Directly comparable to 3D BioFibR on the SpidrFibR spider silk program — both are working on scalable recombinant spider silk — though Spiber is significantly larger and more commercially advanced in apparel.

TypeDirect peer
Description

Modern Meadow is a U.S. biotech developing bioengineered collagen and other protein-based materials for consumer products and materials applications. Comparable to 3D BioFibR as a bioengineered protein-fiber platform company targeting non-medical and medical markets, with a broader near-term focus on materials/textile applications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

3D BioFibR

Biopolymer Fiber Materials3dbiofibr.com

3D BioFibR is a Halifax-based biotech company that uses patented automated dry-spinning technology to manufacture commercial-scale collagen and other biopolymer fibers for tissue engineering, 3D bioprinting, and regenerative medicine researchers worldwide.

What 3D BioFibR does

3D BioFibR is a Halifax, Nova Scotia-based biotechnology and advanced materials company founded in 2020 that commercializes a patented automated dry-spinning platform for producing biomimetic protein fibers at commercial scale. The company's flagship CollaFibR® product line consists of collagen fibers that closely replicate the structure, biomechanics, and biochemistry of natural collagen, with the company claiming over 1000x the throughput of competing technologies and first-mover status in commercial-scale collagen fiber spinning. The same platform has been used to produce recombinant spider silk (SpidrFibR™ — claimed to be five times stronger than steel), fibrin, and chitosan, indicating applicability across multiple network-forming biopolymers. The company is led by CEO Kevin Sullivan (23+ years of biotech leadership and a prior TSX IPO) and CSO Dr. John Frampton (Tier II Canada Research Chair at Dalhousie University, 40+ publications, 2 patents).

3D BioFibR generates revenue through three channels: direct e-commerce sales of two catalog SKUs (μCollaFibR™ Additive for Bioinks and Hydrogels, and CollaFibR® 3D Scaffold for Cell Culture) via its own online storefront; regional distribution through five specialty life-science distributors (AMSBIO in the Americas/Europe, AMS Biotechnology in Europe, Cell & Gene BioSolutions in India, Sciencewerke in Singapore/Malaysia, and Filgen in Japan); and project-based custom non-woven collagen scaffold manufacturing for enterprise tissue-engineering customers. Bespoke co-development engagements include a 'bionic' nerve project with ReNerve and a plant-based recombinant human collagen program with PlantForm Corporation (supported by $1.3M from NGen). Customers are primarily academic and commercial tissue-engineering, 3D bioprinting, and regenerative medicine researchers, with secondary exploration of advanced-materials verticals such as green textiles, aerospace, and defense.

The company is privately held and venture-backed, having raised approximately CAD $8.07M in equity across four rounds (October 2020, September 2021, July 2023, and June 2025) plus CAD $1.5M in non-dilutive grants from ACOA and NGen. Current capital priorities are manufacturing capacity expansion and the construction of a new clean room in Halifax for medical-grade materials production. The 11–50-person organization was recognized as Most Innovative Company at the 2024 Discovery Awards and is positioning for regulated tissue-engineering and regenerative-medicine supply as its manufacturing footprint scales.

3D BioFibR firmographics

Firmographics
Name
3D BioFibR
Legal name
3DBioFibR Inc.
Website
https://3dbiofibr.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
3D BioFibR is a Halifax-based biotech company that uses patented automated dry-spinning technology to manufacture commercial-scale collagen and other biopolymer fibers for tissue engineering, 3D bioprinting, and regenerative medicine researchers worldwide.
Ownership category
akta.pro rank

3D BioFibR industry classification

Industry
Product category
Biopolymer Fiber Materials
NAICS
Plastics Material and Resin Manufacturing (325211), Resin and Synthetic Rubber Manufacturing (32521)
SIC
Plastic Materials, Synth Resins & Nonvulcan Elastomers (2821), Plastic Material, Synth Resin/Rubber, Cellulos (No Glass) (2820)
akta.pro industry
PRIMARYIMANAAAG
Bio-based & Biodegradable Polymer Resin Manufacturing (PLA, PHA, PBS, starch blends)
SECONDARYIMAAADAA
Polymer 3D Printing Service Bureaus (FDM/FFF, SLA/DLP, SLS/MJF)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Services (On-Demand Manufacturing & Service Bureaus)

Keywords

  • Biopolymer fiber manufacturing
  • Collagen fiber products
  • Tissue engineering materials
  • Dry-spinning technology
  • 3D bioprinting materials

Where 3D BioFibR is headquartered

Location

Headquarters

HQ city
Halifax
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

3D BioFibR business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Direct product sales via e-commerce storefront: Online storefront at shop.3dbiofibr.com sells CollaFibR tissue engineering products directly to end users, including μCollaFibR™ additive for bioinks and hydrogels and CollaFibR® 3D Scaffold for Cell Culture. Transactional, unit-priced purchases.
  2. Distributor-led sales in regional markets: Revenue generated through regional distribution partners (AMSBIO in Americas/Europe, Cell & Gene BioSolutions in India, Sciencewerke in Singapore & Malaysia, Filgen in Japan) reselling CollaFibR products to local research customers.
  3. Custom scaffold manufacturing services: Project-based custom non-woven collagen scaffold manufacturing for tissue engineering customers with bespoke specifications, sold directly via the company.
  4. Non-dilutive co-development and grant funding: Funding from Next Generation Manufacturing Canada ($1.3M) and ACOA ($200,000) supporting R&D and automation projects. While not core revenue, supports scaling of commercial product offerings.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goCollaFibR products sold via online storefront and regional distributors; specific prices not publicly listed

Go-to-market motion4 records

Distribution channels7 records

Marketing channels5 records

3D BioFibR product offering

Product offering

Core offering

3D BioFibR manufactures biomimetic collagen fibers and other biopolymer fibers using its patented, fully automated dry-spinning technology, delivering over 1000X the throughput of competing approaches. The company sells its CollaFibR® product family (μCollaFibR™ Additive for Bioinks and Hydrogels and CollaFibR® 3D Scaffold for Cell Culture) directly and via a global distributor network for tissue engineering, 3D bioprinting, and cell culture applications, and offers bespoke Custom Scaffolds and the SpidrFibR™ spider silk prototype.

Product overview

3D BioFibR is a biotech company built around a single patented, fully automated dry-spinning platform that produces biopolymer fibers at commercial scale (over 1000× the throughput of competing technologies). The platform's flagship output is the CollaFibR® family of collagen fibers, which replicate the structure, biomechanics, and biochemical properties of natural collagen. CollaFibR® is commercialized as two catalog SKUs — μCollaFibR™ Additive for Bioinks and Hydrogels and CollaFibR® 3D Scaffold for Cell Culture — sold directly and through a global distributor network (AMSBIO in the Americas/Europe, Cell & Gene BioSolutions in India, Sciencewerke in Singapore/Malaysia, and Filgen in Japan). Beyond collagen, the same dry-spinning platform is used to spin other network-forming biopolymers, exemplified by the SpidrFibR™ recombinant spider silk prototype. Custom non-woven collagen scaffolds for tissue engineering are offered on a made-to-order basis through the Custom Scaffolds line, and the company is collaborating with PlantForm Corporation on plant-based recombinant human collagen fiber production and with ReNerve on a 'bionic' nerve project.

Differentiator

Problem solved

Functional benefit

Brands

  • CollaFibR: Patented collagen fiber product line produced using 3DBioFibR's dry-spinning technology, including the μCollaFibR additive for bioinks and hydrogels and the CollaFibR 3D Scaffold for cell culture. Used for 3D bioprinting, hydrogels, and tissue engineering applications.
  • SpidrFibR
  • μCollaFibR

Products and services

  • μCollaFibR™ Additive for Bioinks and Hydrogels 50 μm type I collagen fibers used as an additive for bioinks and hydrogels, universally compatible with bioprinting materials and modalities, chemically stable in solvents with pH >2, and acts as a physiologically relevant site for cell attachment while improving shape fidelity of bioprinted constructs. For tissue engineering and 3D bioprinting researchers.
  • CollaFibR® 3D Scaffold for Cell Culture 100 μm porous collagen fiber scaffold resembling natural three-dimensional collagen structures, produced using automated robotics and GMP grade type I collagen (bovine) for high batch-to-batch consistency, provided in user-friendly 12-well plate inserts and compatible with brightfield, epifluorescence, confocal, and live cell microscopy. For tissue engineering researchers.
  • SpidrFibR™ Recombinant Spider Silk Recombinant spider silk prototype produced using 3D BioFibR's patented dry-spinning technology, described as five times stronger than steel and more extensible than rubber. Targeted at green textiles, aerospace engineering, and defense applications.
  • Custom Scaffolds Bespoke non-woven collagen scaffolds for tissue engineering produced via 3D BioFibR's patented dry-spinning technology, sold directly to clients with project-based specifications.

Quantifiable outcome

  • Over 1000X the throughput of competing dry-spinning/collagen technologies
  • +3 more outcomes

Companies that use 3D BioFibR

Customer profile

Segments4 records

Ideal customer profiles4 records

3D BioFibR technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

3D BioFibR partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and supporting.

  • PlantForm CorporationcoreStrategic or Co-development Partner · 18 January 2024PlantForm Corporation is a co-development collaborator that received $1.3M from NGen jointly with 3D BioFibR. The project combines PlantForm's plant-based biologics platform with 3D BioFibR's fiber manufacturing technology to produce collagen fibers that mimic natural properties.
  • ReNervecoreStrategic or Co-development Partner · 28 June 2023ReNerve and 3D BioFibR partnered for a 'bionic' nerve project to develop nerve repair solutions using CollaFibR collagen fiber technology.
  • AMSBIO LLC.coreChannel Partner/ Reseller/ DistributorAMSBIO LLC. is 3D BioFibR's distributor for the Americas, based at 1035 Cambridge Street, Suite 11 B, Cambridge, MA 02141. They resell CollaFibR tissue engineering products via their website (amsbio.com).
  • AMS Biotechnology (Europe) Ltd.coreChannel Partner/ Reseller/ DistributorAMS Biotechnology (Europe) Ltd. is 3D BioFibR's European distributor, based at 184 Park Drive, Milton Park, Abingdon OX14 4SE, U.K. They resell CollaFibR products to research customers across Europe.
  • Cell & Gene BioSolutionssupportingChannel Partner/ Reseller/ DistributorCell & Gene BioSolutions is 3D BioFibR's distributor in India, based at 418-B Rampriya Brundavan Gardenia, 4th Main, 4th Cross, Hanumgiri, Arehalli, Bangalore-560061, Karnataka, India.
  • Sciencewerke Pte LtdsupportingChannel Partner/ Reseller/ DistributorSciencewerke Pte Ltd is 3D BioFibR's distributor for Singapore and Malaysia, based at 102E Pasir Panjang Rd #08-03 Citilink Warehouse Complex, Singapore 118529.
  • Filgen Inc.supportingChannel Partner/ Reseller/ DistributorFilgen Inc. is 3D BioFibR's distributor in Japan, based at 02E Pasir Panjan 1-409, Jonoyama, Midori-ku, Nagoya, Aichi-pref. 459-8011, Japan.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

3D BioFibR competitors and assessment

Company assessment

Broad incumbents

  • Collagen Solutions (Rousselot): Rousselot (which acquired Collagen Solutions) is a global leader in collagen-based solutions for biomedical, pharmaceutical, and food applications. Directly comparable to 3D BioFibR as a supplier of medical-grade collagen materials for tissue engineering and regenerative medicine, but at significantly larger scale with established GMP manufacturing.
  • Cellink (BICO Group): BICO/Cellink is a global bioconvergence company providing bioprinters, bioinks, and biomaterials for 3D cell culture and tissue engineering. Comparable to 3D BioFibR as a supplier into the bioprinting workflow, but at much broader portfolio scale and with bioprinter hardware alongside bioinks.
  • Collagen Matrix Inc. Collagen Matrix is a U.S. manufacturer of collagen and other natural polymer-based medical devices for tissue repair and regeneration. Comparable to 3D BioFibR as a medical-grade collagen products supplier, but operating at larger scale with established FDA-cleared products.
  • DSM Biomedical: DSM Biomedical (part of dsm-firmenich) is a global supplier of biomaterials including collagen, hyaluronic acid, and resorbable polymers for medical devices and tissue engineering. Comparable to 3D BioFibR as a regulated medical-grade biomaterials supplier, but at vastly larger scale and broader portfolio scope.
  • Corbion (biomaterials): Corbion is a Dutch biobased ingredients company with biomedical-grade biopolymers used in medical devices and regenerative medicine. Comparable to 3D BioFibR as a biomaterials supplier targeting medical and life-science customers, but at much broader scope and corporate scale.

Direct peers

  • Advanced BioMatrix: Advanced BioMatrix is a U.S.-based supplier of collagen, hyaluronic acid, and other extracellular matrix products used in 3D bioprinting, tissue engineering, and cell culture. Directly comparable to 3D BioFibR as a catalog supplier of biomaterials to the same research-tool and tissue-engineering customer base, though without a dry-spinning fiber platform.
  • Jellagen Pty Ltd: Jellagen manufactures marine (jellyfish) collagen-based biomaterials for medical devices, 3D cell culture, and tissue engineering. Directly comparable to 3D BioFibR as a specialist collagen supplier targeting the same research and regenerative-medicine segments, with a differentiated raw material source.
  • Matricel GmbH: Matricel is a German manufacturer of collagen-based scaffolds and medical devices for tissue engineering and regenerative medicine. Directly comparable to 3D BioFibR as a specialist collagen scaffold producer, though focused on processed collagen matrices rather than spun collagen fibers.
  • Spiber Inc. Spiber is a Japanese biotechnology company producing Brewed Protein (recombinant spider silk) materials for textiles, automotive, and other applications. Directly comparable to 3D BioFibR on the SpidrFibR spider silk program — both are working on scalable recombinant spider silk — though Spiber is significantly larger and more commercially advanced in apparel.
  • Modern Meadow: Modern Meadow is a U.S. biotech developing bioengineered collagen and other protein-based materials for consumer products and materials applications. Comparable to 3D BioFibR as a bioengineered protein-fiber platform company targeting non-medical and medical markets, with a broader near-term focus on materials/textile applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

3D BioFibR social profiles

Digital presence

3D BioFibR financial estimates

Financial estimate

Revenue estimate

Valuation estimate

3D BioFibR leadership team

Management profile

Number of profiles

Profiles5 records

3D BioFibR funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

3D BioFibR M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 3D BioFibR

What does 3D BioFibR do?

3D BioFibR manufactures biomimetic collagen fibers and other biopolymer fibers using its patented, fully automated dry-spinning technology, delivering over 1000X the throughput of competing approaches. The company sells its CollaFibR® product family (μCollaFibR™ Additive for Bioinks and Hydrogels and CollaFibR® 3D Scaffold for Cell Culture) directly and via a global distributor network for tissue engineering, 3D bioprinting, and cell culture applications, and offers bespoke Custom Scaffolds and the SpidrFibR™ spider silk prototype.

Is 3D BioFibR a public or private company?

3D BioFibR is a private company. It is classified as venture growth investor backed and is currently operating.

When was 3D BioFibR founded?

3D BioFibR was founded in 2020. It employs 11 to 50 people.

Where is 3D BioFibR based?

3D BioFibR is headquartered in Halifax, Canada, in the North America region.

How does 3D BioFibR make money?

Four revenue lines are on record. Direct product sales via e-commerce storefront is the primary driver. The others are distributor-led sales in regional markets, custom scaffold manufacturing services and non-dilutive co-development and grant funding.

Who are 3D BioFibR's main competitors?

Broad incumbents on record are Collagen Solutions (Rousselot), Cellink (BICO Group), Collagen Matrix Inc., DSM Biomedical and Corbion (biomaterials). Direct peers are Advanced BioMatrix, Jellagen Pty Ltd, Matricel GmbH, Spiber Inc. and Modern Meadow.

Does 3D BioFibR have an API?

No public API is recorded for 3D BioFibR.

What industry is 3D BioFibR in?

3D BioFibR's product category is Biopolymer Fiber Materials. Its primary akta.pro industry code is IMANAAAG, Bio-based & Biodegradable Polymer Resin Manufacturing (PLA, PHA, PBS, starch blends), with a secondary code of IMAAADAA, Polymer 3D Printing Service Bureaus (FDM/FFF, SLA/DLP, SLS/MJF). Its NAICS code is 325211 and its SIC code is 2821.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EntrevestorEntrevestorTen startups pitched investors at BioPort Atlantic's Innovator Showcase, marking the conference's 25th year. The three-day event in Halifax featured companies like BioLabMate, ClinicGlide, and Ring Rescue, with pitches covering bioplastics, AI healthcare tools, and medical devices.EntrevestorEntrevestorThree Atlantic Canadian startups won $325,000 at Startupfest in Montreal, taking over one-third of the $825,000 prize money. AgroGene Solutions, Finleaf Technologies, and 3dBioFibR each received six-figure prizes, with AgroGene winning the headline $100,000 Best of the Fest Investment Prize.Private Capital Journal3DBioFibR secures $3M new financing3DBioFibR Inc., a Halifax-based manufacturer of advanced biopolymer fibers, has raised $3 million in equity funding from investors including Invest Nova Scotia, AoA Innovation Fund, Build Ventures, and Concrete Ventures. The funding will support increased manufacturing capacity, operational growth, and ISO 13485 certification, including construction of a clean room manufacturing facility for medical-grade materials. The company has been securing paid development agreements with global companies in tissue engineering, medical devices, defense, cosmetics, and apparel sectors.BioProcess InternationalPlant-Based Recombinant Human CollagenPlantForm Corporation, a Canadian biotechnology company, is developing plant-based recombinant human collagen using its vivoXPRESS platform with Nicotiana benthamiana plants to address the growing demand for vegan collagen alternatives in cosmetics, supplements, and regenerative medicine. The company has partnered with 3DBioFibR Inc., with both firms receiving $1.3 million in funding from Next Generation Manufacturing Canada to develop scalable dry spinning of recombinant human collagen fibers for commercial-scale medical applications. The plant-based expression system enables proper proline hydroxylation of collagen—a capability that other microbial and insect-cell systems cannot achieve—while offering lower production costs and easier scalability compared to traditional cell-culture methods.Dalhousie UniversityWhere Ideas Meet Impact: How Dal researchers spun a bioengineering discovery into a medical industry innovation3DBioFibR Inc. was spun out of Dalhousie University's School of Biomedical Engineering three and a half years ago, commercializing research led by Dr. John Frampton on manufacturing protein fibers for tissue engineering. The team successfully increased collagen content from two percent to 100 percent and developed the first fully automated manufacturing system for collagen fibers, enabling potential biomedical applications such as nerve and cartilage repair. The company, led by CEO Kevin Sullivan with Gurkaran Chowdhry as Director of Business Development, is now focused on scaling the technology for commercial use in the medical industry.EntrevestorEntrevestorHalifax-based 3D BioFibR and Toronto-headquartered PlantForm Corporation are receiving $1.3 million in funding from Next Generation Manufacturing Canada (NGen) to scale the production of recombinant human collagen. The collaboration will utilize PlantForm's vivoXPRESS plant-based platform combined with 3D BioFibR's automated manufacturing technology to produce commercial-scale biofibres for the medical research market.Business Wire Blog3D BioFibR Raises $3.52M to Bring its Premium Collagen Fiber Products to Market3D BioFibR raised over $3.52M in seed financing led by Invest Nova Scotia. The funds will expand its facilities to include a climate-controlled biomanufacturing cleanroom and bring premium collagen fiber products to market. The company's proprietary dry-spinning process is at least 3,600x faster than competing methods.3DHealsBiomaterials Bioinks for 3D Printing3DHEALS is hosting a webinar featuring experts from companies such as 3Deus Dynamics, 3D BioFibR Inc., and Bezwada Biomedical to discuss the development of biomaterials and bioinks for 3D printing in healthcare. The event highlights advancements in tissue engineering, regenerative medicine, and the commercialization of bioprinting technologies through strategic partnerships and product launches. Speakers will cover the current status and future outlook of these materials for personalized medical treatments.Canada.ca3D BioFibR weaving new research opportunitiesThe Government of Canada, through the Atlantic Canada Opportunities Agency, announced a $200,000 repayable contribution to 3D BioFibR Inc. to support the automation of its dry-spinning manufacturing process. This funding aims to help the Halifax-based company increase productivity, ensure consistency in its biofiber production for industrial applications, and hire two researchers.BioWorldCanadian company wins funding to develop super strong biofibers3D Biofibr Inc. raised CA$550,000 in seed funding to develop and scale a biofilm platform that mimics spider spinning. The Canadian med-tech company aims to commercialize the technology, with the funding supporting research and development.